<DOC>
	<DOCNO>NCT01222546</DOCNO>
	<brief_summary>This open-label , multi-center , dose-escalation Phase I study evaluate safety , pharmacokinetics activity CH5132799 administer orally single agent patient advance solid tumor .</brief_summary>
	<brief_title>Study CH5132799 Administered Orally Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Provision sign write informed consent . 2 . Histologically cytologically confirm diagnosis advance solid tumor . 3 . Age ≥ 18 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . 5 . Life expectancy ≥ 12 week . 6 . Disease measurability : Patients must measurable per Response Evaluation Criteria Solid Tumours ( RECIST ) criteria version 1.1 and/or evaluable disease . 7 . Paraffinembedded archival tumor tissue available . Fresh biopsy require paraffin embed tumor tissue available . 8 . Adequate bone marrow function . 9 . Adequate cardiac function : Patient Left Ventricular Ejection Fraction ( LVEF ) ≥ 50 % determine echocardiography ( ECHO ) Multi Gated Acquisition ( MUGA ) scan . 10 . Adequate liver function . 11 . Adequate renal function . 12 . Adequate adrenal function assess baseline cortisol &gt; 200 nmol/L 13 . Ability comply protocol requirement . 14 . Female patient must postmenopausal ( 12 month amenorrhea ) , surgically sterile must agree use physical method contraception . Male patient sterilize must agree use barrier method contraception . Male subject must also commit use barrier method contraception least 3 month end study treatment . 15 . Female patient childbearing potential must negative serum pregnancy test within seven day prior first study drug administration . 1 . History allergic reaction attribute component formulate product . 2 . Inability swallow oral medication impair gastrointestinal absorption due active inflammatory bowel disease . 3 . Known Central Nervous System ( CNS ) metastases leptomeningeal metastasis eligible could radiologically demonstrate CNS disease progression 3 month prior study 4 . Known active uncontrolled pulmonary dysfunction . 5 . Uncontrolled hypertension 6 . Prior chemotherapy , radiotherapy ( short cycle palliative radiotherapy bone pain ) , immunotherapy within 28 day first receipt study drug ( within 6 week nitrosoureas mitomycin C ) . Hormone therapy within 14 day first receipt study drug , exception prostate cancer indicate . 7 . Prior toxicity chemotherapy radiotherapy regress Grade ≤ 1 severity National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE version 4.0 ) . 8 . Type 1 2 diabetes mellitus require regular medication and/or fast plasma glucose ( FPG ) ≥ 120 mg/dL ( 6.6 mmol/dL ) screening . 9 . Increased QTc interval ( QTc &gt; 450 m male ; &gt; 460 m female ) . 10 . History heart failure , refractory hypokalemia adequate supplementation , family history long QT syndrome risk factor `` Torsades de Pointes '' , and/or use concomitant medication prolong QT/QTc interval . 11 . Prior corticosteroid therapy within 14 day first receipt study drug . 12 . Treatment investigational agent within 28 day first receipt study drug . 13 . Acute chronic infection . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find medical condition , opinion investigator , contraindicate use investigational drug , impose excessive risk patient . 14 . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection . 15 . History clinically significant bowel disease include abdominal fistula , gastrointestinal perforation , diverticulitis . 16 . Major surgery within 28 day first receipt study drug . 17 . Pregnant lactate woman 18 . Altered mental status psychiatric disorder , opinion investigator , would preclude valid patient inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>